FCER2 and asthma: This outcome is most likely attributed to ligelizumab’s inefficiency in blocking the function of the FcεRII/CD23 receptor, which is responsible for the inflammatory response in asthma, as indicated by in vitro data coupled with drug concentration analysis [41].